PCM
PCVX icon

Penserra Capital Management’s Vaxcyte PCVX Stock Holding History

Penserra Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,195
Closed -$30K – 1501
2021
Q3 		$30K Buy
1,195
+25
+2% +$606 ﹤0.01% 1184
2021
Q2 		$26K Buy
1,170
+20
+2% +$409 ﹤0.01% 1110
2021
Q1 		$22K Sell
1,150
-30
-3% -$755 ﹤0.01% 960
2020
Q4 		$31K Buy
+1,180
New +$43.9K ﹤0.01% 770

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's PCVX Position: Q4 2021 in Review

Penserra Capital Management sold out of Vaxcyte (PCVX) in Q4 2021, closing a stake of 1,195 shares — an estimated $30K sold.

Penserra Capital Management first reported a position in PCVX in Q4 2020 and held it in 4 quarters. The position peaked at $31K in Q4 2020. 87 funds tracked by Wall St. Rank hold PCVX as of Q4 2021.

  • Penserra Capital Management reported no remaining Vaxcyte position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,195 Vaxcyte shares in Q4 2021, an estimated $30K.
  • Penserra Capital Management first reported a position in Vaxcyte in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Vaxcyte position peaked at $31K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.